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Zusammenfassung 
 
In hormonsensitiven Epithelien wird eine Steigerung des Glukosetransports hauptsächlich durch 
vermehrten Transport der Hexosetransporter-Isoformen GLUT1(SLC2A1) und GLUT4(SLC2A4) 
von intrazellulären Kompartimenten zur Plasmamembran erreicht. Es ist bereits bekannt, daß die 
Inhibition der PI3K die Stimulation der GLUT1 und GLUT4 Translokation durch Insulin und 
damit eine Erhöhung des Glukosetransports unterbindet. Die Serum- und Glukokortikod-
induzierbare Kinase (SGK) 1 ist eine weitere Kinase abwärts der PI3K. 
 
Die SGK1 ist eine Proteinkinase, welche die Funktion und Expression einer Reihe von 
Ionenkanälen und Transportern reguliert. Sie wurde als ein Gen identifiziert, welches akut in 
Brusttumorzellen und Fibroblasten durch die Applikation von Serum- und Glukokortikoiden 
stimuliert wird. Die Kinase wird durch Faktoren phosphoryliert, welche die PI3K aktivieren. Die 
Phosphorylierung erfolgt durch die 3-Phosphoinositid-abhängigen Kinasen (PDK) 1 und PDK2. 
In der phosphorylierter Form reguliert die Kinase die Aktivität ihrer Ziele durch 
Phosphorylierung an der SGK Konsensusstelle (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr). 
 
GLUT1 enthält eine Konsensusstelle (95Ser) für die Phosphorylierung durch SGK1. während sich 
die Phosphorylierungsstelle auf dem GLUT4 an der Position 274Ser befindet. Die vorliegende 
Studie untersucht die Hypothese, daß GLUT1 und GLUT4 durch die SGK1 reguliert werden. Zu 
diesem Zweck wurde die cRNA der Glukosetransporter und der Proteinkinase im heterologen 
Expressionssystem des Xenopus laevis Oocyten exprimiert. Die Quantifizierung der 
Transporteraktivität erfolgte durch die Bestimmung der Aufnahme von radioaktiver 
Deoxyglukose. In den betreffenden Studien  in Xenopus laevis Oocyten und Adipocyten konnte 
nachgewiesen werden, dass die GLUT1 Aktivität durch die konstitutiv aktive SGK1 stimuliert 
wird. 
 
Dieser Prozeß benötig eine intakte Katalysierungsstelle auf der SGK1, da die inaktive K127NSGK 
keinen Effekt auf den Transporter zeigt. Es konnte ebenfalls gezeigt werden, daß die Stimulierung 
des GLUT1 durch die S422DSGK1 nicht auf einer Erhöhung der GLUT1 de novo Synthese beruht 
sondern vielmehr auf einer Erhöhung der GLUT1-Abundanz an der Zelloberfläche. Die kinetische 
Analyse zeigte, daß die Stimulierung des GLUT1 zwar die maximale Transportrate, nicht aber 
dessen Affinität zum Substrat erhöht. 
 
 Durch Tracer-Flux-Studien in HEK-293 Zellen konnte gezeigt werden, dass GLUT1 durch die 
konstitutiv aktive SGK1 reguliert wird. Dieser Effekt benötigt eine intakte katalytische Aktivität 
der SGK1 da die inaktive SGK1 den Transporter nicht regulierte. Die kinetische Analyse in HEK-
293 Zellen zeigte außerdem, daß die Aktivität des Transporters durch eine Erhöhung der 
maximalen Transportrate erreicht wird, die Substrataffinität aber unbeeinflusst bleibt. Außerdem 
konnte gezeigt werden, das der GLUT1-vermittelte Glukosetransport in Adipozyten von  SGK1-
knockout Mäusen verringert ist. 
 
In der Zusammenfassung werden die Glukosetransporter GLUT1 und GLUT4 durch die 
Glukokortikod-induzierbare Kinase SGK1 moduliert. Die Kinase stimuliert den Transporter durch 
die Erhöhung seiner Zelloberflächenexpression. Die SGK1-abhängige Regulation der 
Glukosetransporter GLUT1 und GLUT4 könnte an der Anpassung der zellulären 
Glukoseaufnahme an den Bedarf der Zelle beteiligt sein. 
 SUMMARY 
 
Insulin stimulates glucose transport in hormone responsive tissues mainly by inducing the 
redistribution of the facilitated hexose carrier isoforms GLUT1 (SLC2A1) and GLUT4 (SLC2A4) 
from intracellular compartments to the plasma membrane. Previous studies have shown that 
phosphatidylinositol 3-kinase (PI-3K) inhibition disrupts the ability of insulin to stimulate GLUT1 
and GLUT4 translocation into the cell membrane and thus glucose transport. The Serum and 
Glucocorticoid inducible Kinase 1 SGK1 is a protein kinase which regulates the function and 
expression of several ion channels and transporters. It was initially recognized as an immediate 
early gene whose mRNA level is increased in mammary tumour cell and fibroblast cell lines upon 
serum or glucocorticoids. The kinase is activated by phosphorylation in response to signals that 
stimulate phosphatidylinositol 3-kinase. The phosphorylation is mediated by 3-phosphoinositide-
dependent protein kinase1 (PDK1) and PDK2/H-motif kinase. Once phosphorylated, the kinase 
regulates its targets activity directly through phosphorylation at the SGK1 consensus site  or 
indirectly through phosphorylation of the ubiquitin ligase or binding to the scaffolding protein 
NHERF2.  
 
GLUT4 contains a putative SGK1 consensus site at 274Ser for phosphorylation by SGK1 and 
GLUT1  at 95Ser. Thus, in the present work it was investigated whether SGK1 regulates GLUT1 
and GLUT4. To this end, membrane proteins encoding the glucose transporter and the kinases 
were expressed heterologously in Xenopus laevis oocytes. Tracer flux studies with 2 De-oxy 
glucose as a substrate and uptake was determined as a measure of GLUT4 activity. The concerned 
studies in oocytes demonstrated that GLUT4 activity is enhanced by constitutively active SGK1. 
The effect requires the kinase catalytical activity since the inactive mutant K127NSGK1 failed to 
modulate the facilitative GLUT4. Deleting the SGK1 phosphorylation site on GLUT4 (S274AGLUT4) 
abrogated the kinase effects suggesting that the action of SGK1 occurs via  direct phosphorylation.  
We also found that GLUT4 stimulation by S422DSGK1 is not due to de novo protein synthesis but 
rather to an increase of the transporter´s abundance in the plasma membrane. Kinetic analysis 
revealed that SGK1 enhances maximal transport rate without altering GLUT4 substrate affinity.  
 
The effect of SGK1 on GLUT1 was examined in the mammalian renal cell line HEK 293. Cells 
were transfected with the empty vector or with SGK1 and 2-Deoxy-glucose uptake determined. 
Tracer flux studies in HEK-293 mammalian cells demonstrated that GLUT1 is regulated by the 
SGK1 kinase in its constitutively active form.  The effect requires the catalytical activity since the 
 inactive mutant form of SGK1 failed to upregulate GLUT1.  Kinetic analysis in HEK-293 cells 
revealed that SGK1 upregulates the transporter activity by enhancing the maximal transport rate 
without altering its substrate affinity. In order to pursue the physiological relevance of SGK1 
mediated regulation of glucose transport adipocytes were isolated from mice lacking SGK1 kinase 
and glucose uptake was measured. Results demonstrated that glucose transport is reduced in 
isolated adipocytes from SGK1 knockout mice as compared to wild type littermates. 
 
In conclusion, the facilitated glucose transporters GLUT1 and GLUT4 are modulated by the serum 
and glucocorticoid inducible kinase SGK1. The kinase stimulates GLUT1 and GLUT4 by 
enhancing the transporter plasma membrane abundance. The SGK1 dependent regulation of these 
two glucose transporters GLUT1 and GLUT4 may participate in the PI3 K-dependent adjustment 
of cellular glucose uptake to the demand. 
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1. INTRODUCTION 
1.1. Diabetes Mellitus 
 
Human bodies need to maintain a glucose concentration level in a narrow range (70 - 109 
mg/dl or 3.9 - 6.04 mmol/l). If the glucose concentration level is significantly out of the 
normal range (70 - 110 mg/dl), this person is considered to have hyperglycaemia (140 mg/dl 
or 7.8 mmol/l after an oral glucose tolerance test, or 100 mg/dl or 5.5 mmol/l after a fasting 
glucose tolerance test) or hypoglycaemia (less than 40 mg/dl or 2.2 mmol/l).  Diabetes 
mellitus is a disease in the glucose-insulin endocrine metabolic regulatory system, in which 
the pancreas either does not release insulin or does not properly use insulin to uptake 
glucose in the plasma (1)  (2)  which is referred as hyperglycaemia.  The consequences are 
that the body does not metabolize the glucose and builds up hyperglycaemia which 
eventually damages the regulatory system. Complications of diabetes mellitus include 
retinopathy, nephropathy, peripheral neuropathy and blindness (3). Diabetes mellitus is one 
of the worst diseases with respect to size of the affected population. The world wide 
diabetics affected population is much higher, especially in underdeveloped countries. 
 
Diabetes mellitus is currently classified as type 1 or type 2 diabetes (2). Type 1 diabetes was 
previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. It 
develops when the body’s immune system destroys pancreatic beta cells, the only cells in the 
body that synthesize the hormone insulin, which regulates blood glucose. This form of 
diabetes usually strikes children and young adults, although disease onset can occur at any 
age. Type 1 diabetes may account for 5% to 10% of all diagnosed cases of diabetes. Risk 
factors for type 1 diabetes include autoimmune, genetic, and environmental factors. Type 2 
diabetes is adult onset or non-insulin-dependent diabetes mellitus (NIDDM) as this is due to 
a deficit in the mass of β cells, reduced insulin secretion (4), and resistance to the action of 
insulin. The relative contribution and interaction of these defects in the pathogenesis of this 
disease  remains to be clarified (5). About 90% to 95% of all diabetics diagnose type 2 
diabetes. Type 2 diabetes is associated with older age, obesity, family history of diabetes, 
prior history of gestational diabetes, impaired glucose tolerance, physical inactivity, and 
race/ethnicity. African Americans, Hispanic/Latino Americans, native Americans, some 
Asian Americans, native Hawaiian, and other Pacific Islanders are at particularly high risk 
for type 2 diabetes. Type 2 diabetes is increasingly being diagnosed  
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in children and adolescents.  In addition to type 1 and type 2 diabetes, gestational diabetes is 
a form of glucose intolerance that is diagnosed in some women during pregnancy (1). 
 
Gestational diabetes occurs more frequently among African Americans, Hispanic/Latino 
Americans, and native Americans. It is also more common among obese women and women 
with a family history of diabetes. During pregnancy, gestational diabetes requires treatment 
to normalize maternal blood glucose levels to avoid complications in the infant. After 
pregnancy, 5% to 10% of women with gestational diabetes are found to have type 2 diabetes. 
Women who have had gestational diabetes have a 20% to 50% chance of developing diabetes 
in the next 5-10 years. Other specific types of diabetes result from specific genetic conditions 
such as maturity-onset diabetes of youth, surgery, drugs, malnutrition, infections, and other 
illnesses. Such types of diabetes may account for 1% to 5% of all diagnosed cases of diabetes. 
The relative contribution and interaction of these defects in the pathogenesis of this disease 
remains to be clarified (5). Due to the large population of diabetes patients in the world and 
the big health expenses, many researchers are motivated to study the glucose-insulin 
endocrine metabolic regulatory system so that we can better understand how the mechanism 
functions (6;7) , what causes the dysfunctions of the system, how to detect the onset of the 
either type of diabetes including the so called prediabetes , (2;7) (8) and eventually provide 
more reasonable, more effective, more efficient and more economic treatments to diabetics. 
1.2 Glucose-insulin endocrine metabolic regulatory system 
 
Metabolism is the process of extracting useful energy from chemical bounds. A metabolic 
pathway is a sequence of enzymatic reactions that take place in order to transfer chemical 
energy from one form to another. The chemical adenosine-triphosphate (ATP) is a common 
carrier of energy in a cell. There are two different ways to form ATP by adding one inorganic 
phosphate group to the adenosine-diphosphate (ADP), or adding two inorganic phosphate 
groups to the adenosine-monophosphate (AMP). The process of inorganic phosphate group 
addition is referred to phosphorylation. Due to the fact that the three phosphate groups in 
ATP carry negative charges, it requires lots of energy to overcome the natural repulsion of 
like-charged phosphates when additional groups are added to AMP.  So considerable 
amount of energy is released during the hydrolysis of ATP to ADP. 
In the glucose-insulin endocrine metabolic regulatory system, the two pancreatic endocrine 
hormones, insulin and glucagon, are the primary dynamic factors that regulate the system. 
Glucose stimulates insulin secretion from β-cells by activating two pathways that require  
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metabolism of the sugar: the triggering and the amplifying pathway (9) . In the triggering 
pathway, the facilitative glucose transporter GLUT2  transports the glucose into the β cell. It 
causes the rise in the ratio of ATP/ADP which leads ATP-sensitive K+ channels (KATP 
channels) in the plasma membrane to close. The decreased K+ permeability leads to 
membrane depolarization, opening of voltage-dependent Ca2+ channels, Ca2+ influx, and the 
eventual rise of the cytosolic Ca2+ concentration ([Ca2+]c) that triggers exocytosis of insulin 
containing vesicles. This pathway is also called KATP channel-dependent pathway. Please 
see Figure 1 for an illustration.  The amplifying pathway which is a KATP channel-
independent pathway, simply increases the efficiency of the Ca2+ on exocytosis when the 
concentration of Ca2+ has been elevated. Once insulin has been secreted, the hormone exerts 
its effect by binding to insulin receptors. 
 
Glucose
GLUT2
Glucose
metabolism
ATP
KATP channel opens
Ca2+ influx
Insulin 
granules
Released
granules
 
 
Figure 1.  Pancreatic beta cells secrete insulin when glucose concentration levels are elevated. 
The facilitated glucose transporter GLUT2 transports the glucose into the cell where it is 
phosphorylated by glucokinase. The glucose metabolism causes ATP-sensitive K+channels to close, 
the membrane to depolarize and the Ca2+ channels to open. This triggers a cascade of protein 
phosphorylations  leading to insulin exocytosis. 
 
The insulin receptor is a transmembrane glycoprotein that belongs to the large class of 
tyrosine kinase receptors. Two α subunits and two β subunits make up the insulin receptor. 
The β subunits pass through the cellular membrane and are linked by disulfide bonds  (10) .  
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The insulin receptors are embedded in the plasma membrane of myocytes and adipocytes 
(11). The binding of insulin to the receptors is the initial step in a signal transduction 
pathway, triggering the consumption and metabolism of glucose.  Bound by insulin , the 
insulin receptor phosphorylates several proteins in the cytoplasm, including insulin receptor 
substrates (IRS-1 and IRS-2) that activate Phosphatidylinositol 3-kinase (PI-3-K) leading to an 
increase in the facilitative glucose transporters (GLUT4 and GLUT1) molecules  in the outer 
membrane of muscle cells and adipocytes, and therefore to an increase in the uptake of 
glucose from blood into muscle and adipose tissue. Figure 2 elucidates this signaling 
pathway (12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Insulin signals cells to utilize glucose.  Insulin binds to its receptors on the membrane of 
the cells and induces phosphorylation of  several proteins in the cytoplasm, including insulin receptor 
substrates (IRS-1 and IRS-2) which activate Phosphatidylinositol 3-kinase (PI-3-K) thereby leading to 
an increase in glucose transporter (GLUT1 and GLUT4) molecules in the plasma membrane. GLUT1 
and GLUT4 transport the glucose into the cells efficiently. 
 
The kinetics of insulin receptor binding is complex. The number of insulin receptors of each 
cell changes opposite to the circulating insulin concentration level. Increased insulin 
circulating level reduces the number of insulin receptors per cell and the decreased 
Insulin
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P P
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circulating level of insulin triggers the number of receptors to increase (13). The number of 
receptors is increased during starvation and decreased in obesity and acromegaly (14). The 
affinity of the receptor for the second insulin molecule is significantly lower than for the first 
bound molecule. This may explain the negative cooperative interactions observed at high 
insulin concentrations. That is, as the concentration of insulin increases and more receptors 
become occupied, the affinity of the receptors for insulin decreases (15). Conversely, at low 
insulin concentrations, positive cooperation has been recorded. That is, the binding of insulin 
to its receptor at low insulin concentrations seems to enhance further binding. 
 
The alpha cells in the pancreas release glucagon, a protein hormone that has important 
effects in the regulation of carbohydrate metabolism.  Glucagon mobilizes glucose, fatty 
acids and amino acids from storage into the blood.  When the glucose concentration level in 
the plasma is low, the liver converts glucagon to glucose.  Both insulin and glucagon are 
important in the regulation of carbohydrate, protein and lipid metabolism.  So when the 
plasma glucose concentration level is high, the pancreas initiates the release of insulin from 
beta cells. Insulin then leads to the translocation of GLUT1 and GLUT4 to the plasma 
membrane so that the glucose is transported into the cells where it is converted to energy 
molecules.  These processes lower the concentration of glucose in blood.  When a human`s 
plasma glucose concentration becomes low,  glucogen is released from alpha cells of the 
pancreas.  In the liver glucagon converts glycogen into glucose molecules thereby increasing 
the glucose concentration level in human plasma.  Figure 3 illustrates the glucose-insulin 
endocrine metabolic regulatory system. 
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Figure 3. Glucose- insulin endocrine metabolic regulatory system. The dashed lines indicate that 
exercises and fasting consume glucose and lower the glucose concentration, which signals the 
pancreas to release glucagon in the liver converts glycogen to glucose. The solid lines indicate that 
the glucose infusion elevates the plasma glucose concentration level which signals the pancreas to 
secrete insulin and decrease plasma glucose.  
 
The glucose transport through facilitative glucose transporters into the beta cells, myocytes 
and adipocytes plays a key role in the maintenance of glucose homeostasis. 
 
1.3 The family of facilitative glucose transporters 
Facilitated diffusion of glucose and related hexoses across biological membranes is catalysed 
by members of the SLC2 family, referred to as glucose transporters or GLUTs. These 
transporters function as simple carriers and the movement of hexose across the plasma 
membrane proceeds in the direction imposed by its electrochemical gradient. A common 
structural feature of the SLC2 family members is the presence of 12 transmembrane domains 
(TM) with both the amino and carboxy-terminal ends present on the cytosolic side and a 
unique N-linked oligosaccharide side-chain present either in the first or the fourth 
extracellular loop (16). Signature sequences conserved between the 
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different members of the SLC2 family are present at distinct locations in the primary 
structure. The presence of these sequences, however, does not predict the substrate 
specificity of these transporters. 
Glucose transporters are expressed in every cell of the body, as might be anticipated from the 
key role of glucose in providing metabolic energy and building blocks for the synthesis of 
biomolecules. The specific physiological role of the isoforms expressed in tissues involved in 
the control of glucose homeostasis, i.e. muscle, adipose tissue, liver, pancreatic beta-cells and 
brain, has been studied in greatest detail. Indeed, in these tissues glucose transporters play 
important roles in the control of glucose utilization, glucose production and glucose sensing 
and their dysregulated expression may underlie pathogenetic mechanisms leading to 
development of diabetes mellitus, but also other specific monogenic diseases (17). 
Facilitated diffusion of glucose across plasma membranes has been studied for several 
decades (18). The recognition that human erythrocytes have a high density of glucose 
transporters allowed the initial biochemical purification of this transporter and the 
preparation of specific antibodies. These were then used for initial cloning of a human 
glucose transporter by screening an expression library prepared from a human hepatoma 
cell line (HepG2) (4). This glucose transporter, named GLUT1 (SLC2A1) , was then used for 
subsequent cloning, by low-stringency screening, of GLUT2–5 (SLC2A2, SLC2A3, SLC2A4, 
SLC2A5)  Class I is comprised of the extensively characterized glucose transporters GLUT1 to 
GLUT4, which can be distinguished on the basis of their distinct tissue distributions (GLUT1, 
erythrocytes, brain micro vessels; GLUT2 , liver, pancreatic islets; GLUT3, neuronal cells; 
GLUT4, muscle, adipose tissue) and their hormonal regulation (e.g., insulin sensitivity of 
GLUT4) (19). Class II is comprised of the fructose-specific transporter GLUT5 (20) and three 
related proteins, GLUT7 (SLC1A7), GLUT9 (SLC1A9), and GLUT11 (SLC1A11) (21) For 
GLUT11, fructose-inhibitable glucose transport activity has been demonstrated in a system of 
reconstituted vesicles. Class III is characterized by the lack of a glycosylation site in the first 
extra cellular linker domain and by the presence of such a site in loop 9. HMIT1 (SLC1A13), 
can be included in the class III GLUTs . Glucose transport activity has been demonstrated for 
GLUT6 and GLUT8. It should be emphasized, however, that the designation of the family 
does not necessarily reflect the substrate specificity of its members, which may transport 
sugars or polyols other than glucose (e.g. GLUT5-fructose, MIT1-myoinositol) (20).  
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1.3.1 The facilitative glucose transporters in the CNS and blood brain 
barrier 
Glucose is the preferred energy substrate of the brain. Due to its expression in the 
endothelial cells forming the blood brain barrier, the glucose transporter GLUT1 is essential 
for glucose delivery to the brain (22).Given the fact that the abluminal surface of brain 
capillaries is covered by specialized astrocytic end-feet that also express GLUT1, the 
astrocytes probably constitute a major site of glucose uptake (23) In astrocytes, glucose is 
catabolized by glycolysis to lactate, which may be delivered to neurons through a glial-
specific monocarboxylate transporter (MCT1) and a neuron-specific one (MCT2). In neurons, 
lactate is converted to pyruvate, which enters the tricarboxylic acid cycle to generate ATP. 
Glucose can also be taken up directly by neurons, which express the GLUT3 isoform (24). 
GLUT2 is also expressed in the brain in specific regions such as the hypothalamus and the 
brain stem where it may participate in the mechanisms of glucose sensing involved in the 
control of glucose homeostasis. 
The role of GLUT8 in some specific neurons remains unclear. It is localized to intracellular 
vesicles and may possibly move to the cell surface upon as yet unidentified stimuli (25) . 
Finally, HMIT is expressed in astrocytes and in neurons. In astrocytes, HMIT is both 
intracellular and at the plasma membrane, whereas its subcellular localization in neurons is 
under investigation (26). 
1.3.2 The facilitative glucose transporters as pharmaceutical targets 
Elevation of blood glucose is the main symptom of types 1 and 2 diabetes. The GLUT 
isoforms that transport glucose represent therefore a potential therapeutic target for 
normalizing glycaemia. A compound that increases the Vmax maximal velocity of GLUT1 
would increase whole-body glucose utilization. Given the fact that this isoform is almost 
ubiquitous, such activation could, however, also lead to severe hypoglycaemia. Another 
possible site of action for limiting the blood glucose level would be inhibition of glucose 
absorption in the intestine or reabsorption in the kidney. In the intestine, this could be 
possible by blocking both GLUT2 and the alternative membrane-traffic-based pathway of 
basolateral glucose release. In the kidney, GLUT2 deficiency results in glucose excretion in 
the urine, which decreases glycaemia  (27). Inhibition of GLUT2 specifically in the kidney 
could thus treat hyperglycaemia. However, the sodium dependent glucose transporter 
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SGLT2 (SLC5A1) seems to be a more interesting target in the kidney for this purpose since its 
expression is more limited. 
Type 2 diabetes is characterized by the loss of insulin sensitivity that leads to a decrease in 
GLUT1 translocation to the plasma membrane in response to a high blood glucose. To 
compensate the resulting reduced flux of glucose into muscle and adipocytes, it would be 
useful to find a pharmacological compound that increases the Vmax of GLUT1 for glucose, or 
stimulate its translocation to the cell surface. 
An impaired brain inositol metabolism has been linked to psychiatric diseases, in particular 
bipolar disorders (28). Indeed, current treatments of these mood disorders relies on the use 
of Li+ salts, valproic acid and carbamazepine, drugs whose action may interfere with inositol 
metabolism.(28) It is well established that one mechanism of action of Li+ is the inhibition of 
inositol monophosphate phosphatase and polyphosphoinositide 1-phosphate phosphatase 
(29), which blocks recycling of inositol phosphate and reduces the availability of inositol for 
subsequent cycles of intracellular signal transduction. Inhibition of HMIT could also lead to 
such beneficial effects for bipolar disorders by decreasing the intracellular inositol 
concentration. 
Some members of the GLUT family (GLUT1, 2 and 4) can transport glucosamine, which is 
important in the biosynthesis of glycoproteins and, in particular, glycosaminoglycan 
synthesis in cartilage (30). In association with collagen fibres, these molecules are responsible 
for the resilience of the cartilage to deformation. Destruction of joint cartilage occurs in 
osteoarthritis, and several studies have shown that glucosamine is beneficial for this disease . 
Given the fact that GLUT1 is expressed in chondrocytes, the cells that synthesize cartilage, 
glucosamine has favourable effects for osteoarthritis are probably mediated by transport 
across GLUT1 into these cells. Furthermore, glucosamine absorption seems to be mediated in 
part by GLUT2. This provides an example of the use of GLUT isoforms to deliver therapeutic 
molecules to their site of action. 
1.3.3 The facilitative glucose transporter GLUT1 
GLUT1 cDNA was isolated from an expression library using antibodies against the human´s 
erythrocyte glucose transporter(4). Although cloned from a hepatoma cDNA library, GLUT1 
is not expressed in normal hepatocytes. It is, however, induced during oncogenic 
transformation of most cell types and its expression correlates with the increase in glucose 
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metabolism observed in tumour cells (31). GLUT1 is found in almost every tissue with 
different levels of expression in different cell types. The expression level usually correlates 
with the rate of cellular glucose metabolism. As mentioned above, it is also  expressed highly 
in blood-tissue barriers, in particular in the endothelial cells forming the blood-brain barrier.  
Several heterozygous mutations resulting in GLUT1 haploinsufficiency have been identified. 
These cause hypoglycorrachia, a condition characterized by seizures, developmental delay, 
acquired microcephaly, and hypotonia, and which is due to a decrease rate of glucose 
transport from the blood into cerebrospinal fluid. 
The topological arrangement of GLUT1 within the plasma membrane has been confirmed 
using several experimental approaches. Recently, two models have been proposed for the 
tertiary structure of GLUT1. The first is based on data obtained from cysteine scanning 
mutagenesis of five of the α-helices of GLUT1 together with information from site-directed 
mutagenesis (32). The second is based primarily on the proposed helical bundle arrangement 
of the Lac permease and has been refined using energy minimization algorithm (33) These 
two models describe a key role for helix 7 in the formation of a water-filled channel which 
may form the path for glucose across the plasma membrane. 
The transport of glucose may be described as an alternating confirmation model in which the 
transporter has mutually exclusive binding sites located on the extracellular (import site) and 
on the intracellular face (export site) of the transporter (Figure 4). Binding of glucose to one 
site induces the transporter to switch to the opposite conformation, a process that is 
accompanied by a movement of the substrate across the plasma membrane (34). In human 
erythrocytes, GLUT1 is thought to be present as homodimers or homotetramers, with the 
conversion between both oligomeric forms being dependent on the redox state, . GLUT1 
transports glucose with an affinity constant (Km) of ~3 mM. Other transported substrates are 
galactose (30mM) (34), mannose (35) (20mM) and glucosamine 2.1+0.5mM (36).  Glucose 
transport by GLUT1 is sensitive to several inhibitors that also block transport by other 
isoforms. Many of them are competitive inhibitors of sugar binding, either to the 
extracellular or the cytosolic sugar binding sites. Cytochalasin B binds to the inner surface of 
GLUT1 and inhibits its glucose transport activity with an IC50 of 0.44 µM. Binding of 
cytochalasin B is to a site which contains tryptophan 388 and 412.   Also acting on the same 
intracellular site is the diterpene toxin forskolin. Forskolin has been used as a photoaffinity 
label with some specificity for the glucose transporter and its affinity is increased in the 3-
iodo4-azidophenethylamido-7-O-succinyldeacetyl (IAPS) derivative. An iodinated derivative 
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of forskolin (7-aminoalkylcarbamate) with a very high affinity (IC50 200 nM) has also been 
described (37). 
Glucose transport activity of GLUT1 is inhibited by HgCl2 (IC50 3.5 µM), phloretin (IC50 
49 µM), phlorizin (IC50 355 µM) and 4,6-O-ethylidene-D-glucose (IC50 12 mM), which bind  
to the external glucose binding site where glutamine 161 appears to be critical for inhibitor 
binding (16).   
 
Figure 4.  Conformational model of GLUT1 in the membrane. A The side view of the GLUT1 
protein shows the 12 transmembrane helices with a large intracellular loop connecting helix 6 and 7, 
the N-glycosylation site in the first extracellular loop, and the amino- and carboxy-termini located in the 
cytosol. Conserved motifs within the GLUT family and functional domains such as ATP binding sites, 
phosphorylation sites, and substrate import and export sites are indicated. Also shown are mutations 
(filled circles) identified in patients with GLUT1 deficiency syndrome (GLUT1DS) and amino acids 
(filled grey circles with white centre) analyzed by in-vitro studies]. B End-on view from the extracellular 
surface. Amphipathic helices thought to participate in the glucose channel are shown in black. 
 
1.3.4 Glucose transporter 4 
 
After nutrient intake, the beta cells of the pancreas response by releasing insulin into the 
blood.  The insulin controls many post prandial events in which the localization of the 
glucose transporter in the cytoplasm versus plasma membrane plays an important role. 
Insulin resistance is associated with insufficient recruitment of GLUT4 to the membrane 
despite the protein is expressed in a normal manner. This leads to study the mechanisms 
involved in the insulin regulated GLUT4 translocation and glucose uptake so that effective 
treatment and preventive measures can be achieved. Although there is an improvemnt 
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within the last two decades, the whole mechanism linking insulin to GLUT4 translocation 
have yet to be fully resolved.  
Earlier it was found that, in rat adipocytes insulin triggers the movement of the sugar 
transporter that is found in these cells from cytoplam to the plasma  membrane.  That was 
later confirmed when GLUT4 was identified as the main glucose transporter in these cells. 
GLUT4 primarily found in muscle and fat cells, is found in a complex intracellular tubulo–
vesicular network that is connected to the endosomal–trans-Golgi network (TGN) system. It 
has 12 membrane spanning domains with amino and carboxyl termini in the intracellular 
region. In the basal state, GLUT4 cycles continuously between the plasma membrane and 
one or more intracellular compartments, with 90-95 percent of the transporter residing 
within the cell interior, tightly packaged into vesicles. The overall insulin-induced GLUT4 
vesicle trafficking results in a >10-fold increase of GLUT4 protein at the cell surface (38). 
GLUT4 is found within large tubulo-vesicular structures in the perinuclear region of the cell 
and within small vesicles dispersed throughout the cytoplasm, also known as GLUT4 
storage vesicles (GSVs)  (39) (40). Perinuclear GLUT4 is likely localized in endosomes. GSVs 
on the other hand co-localize with insulin-responsive aminopeptidase (IRAP) and vesicle-
associated membrane protein 2 (VAMP2). Upon insulin stimulation, it appears that GSVs are 
translocated to the cell surface, as there is an increase of GLUT4 at the plasma membrane 
that is proportional to the reduction in GLUT4-containing vesicles from the cytosolic 
compartment (41)  (42), while the level of perinuclear GLUT4-containing vesicles remains 
relatively the same. Furthermore, total internal reflection fluorescence microscopy has 
revealed that in basal adipocytes, GLUT4-containing vesicles are located near the plasma 
membrane and are recruited to the cell surface with insulin stimulation (43) (Figure 2). 
1.3.5 Role of insulin signalling in GLUT4 regulation 
 
Activation of the insulin receptor triggers a cascade of phosphorylation events that 
ultimately promote GLUT4 vesicle exocytosis. The classical insulin signaling pathway 
(Figure 2) involves docking of the insulin receptor substrate (IRS) to the insulin receptor (IR), 
activation of phosphatidylinositol 3-kinase (PI3K) which leads to formation of plasma 
membrane phosphatidylinositol 3,4,5-trisphosphate (PI -P3), subsequent PI -P3-mediated 
activation of Akt and atypical protein kinase C (aPKC). Additionally, a PI3K-independent 
pathway involving c-Cbl, c-Cbl associated protein (CAP), and the GTPase TC10 may also 
regulate GLUT4 translocation. Insulin action is initiated when this peptide hormone binds to 
its receptor. The insulin receptor is composed of two disulphide-linked heterodimers, each of 
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which has an α  and β subunit. Insulin binding to the two high-affinity extracellular α 
subunits leads to activation of intrinsic tyrosine kinase activity of the transmembrane β 
subunits and autophosphorylation of specific tyrosine residues (44), (45). Phosphorylation 
enhances tyrosine kinase activity of the b subunits towards a host of proteins including 
members of the insulin receptor substrate family (IRS-1, -2, -3, -4, -5, and -6), Cbl, SIRP 
(signal regulatory protein) family members, and APS [adapter protein containing a 
pleckstrin homology (PH) and Src-homology 2 (SH2) domain , (46). IRS-1 is found to be  
expressed in the adipose tissues and muscles and IRS-2 in the pancreas and liver.  Studies 
with knockout mouse and siRNA silencing revealed the importance of these substrates in the 
concerned tissues.    
1.3.6 PI3K dependent pathway 
 
Insulin-dependent tyrosine phosphorylation of IRS-1/2 creates docking sites for downstream 
effector molecules including Class IA PI3K.  Activated PI3K catalyzes the phosphorylation of 
PI-P2 on the 3 position of the inositol ring, forming PI-P3. Increased membrane PI-P3 is 
crucial for insulin-stimulated GLUT4 translocation, as this phospholipid provides docking 
sites for downstream molecules via their pleckstrin homology (PH) domains. Inhibition of    
PI-P3 formation with wortmannin or LY29004 effectively blocks insulin-stimulated GLUT4 
translocation and glucose transport (47), (48) . Phosphatase regulators of PI3K generated 
lipids include PTEN and SHIP2. The PTEN catalyzes the dephosphorylation of 
phosphatidylinositols at the D3 position, while the latter catalyzes dephosphorylation of PI -
P3 to yield PI -P2 (49). PI -P3 formation mediates the plasma membrane translocation of two 
PH domain containing proteins which is important for insulin-regulated glucose uptake: Akt 
(protein kinase B, PKB)  and phosphoinositide-dependent-kinase-1 (PDK1).  PDK2 is recently 
identified as the protein kinase mTOR (mammalian target of rapamycin) complexed to the 
regulatory protein rictor (50).  There are three isoforms of protein kinase AKT (1-3) (51) in 
which GLUT4 translocation is dependent on AKT2 (52). AKT2 acts through it downstream 
molecule AS160 (53). AS160 contains a GTPase activating domain for Rabs, small G proteins 
which is involved in the vesicle trafficking (54), (55).  Along with recruiting and activating 
Akt, PI 3,4,5-P3 formation in concert with PDK1 also leads to the activation of atypical 
protein kinase C (aPKC), and both aPKC isoforms z and l have been implicated in GLUT4 
translocation (56). PKC knockout models and expression of kinase-inactive PKC-z/l inhibits 
GLUT4 translocation and glucose uptake in a variety of cell types, and this phenotype can be 
reversed in PKC-l–/– cells by expressing wild-type aPKC. Furthermore, expression of 
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constitutively active aPKC recapitulates the effects of insulin on GLUT4 translocation and 
glucose transport.  
1.3.7 PI3-K independent pathway 
 
It is well established that activation of GLUT4 translocation by insulin requires a PI3K signal 
involving the upstream IR and IRS activators and the downstream Akt and PKC target 
enzymes and AS160 protein.  Some studies over the past decade have also suggested that a 
second pathway occurs as a consequence of Cbl tyrosine phosphorylation (57), (58). Cbl and 
the adaptor protein CAP are recruited to the insulin  receptor by APS (59). Once tyrosine 
phosphorylated by the receptor, Cbl can recruit the adaptor protein CrkII to lipid rafts, along 
with the guanyl nucleotide exchange factor C3G (60). C3G can then activate the GTP-binding 
protein TC10, which resides in lipid rafts . The correct spatial compartmentalization of these 
signaling molecules in the lipid raft microdomain appears to be essential or insulin-
stimulated GLUT4 translocation and glucose transport, as these insulin-mediated events are 
abolished by dominant-interfering mutants of CAP that prevent the localization of Cbl to 
lipid rafts (61). Nevertheless, investigation suggests a role of TC10 in the regulation of actin 
dynamics and phosphoinositides. Cellular cortical actin exists in two forms: monomeric 
globular actin (G-actin) and filamentous actin (F-actin). In the case of cytosketal fusion, 
microtubules and cortical actin plays the important role. When the actin network (62) in 
skeletal muscle is treated with actin depolymerizing agent cytochalasin D or the actin 
monomer binding red sea sponge toxins Latrunculin A or B, it leads to the inhibition of 
glucose uptake and GLUT4 translocation (63). Two potentially overlapping models 
hypothesizing the role of actin in glucose uptake. According to the first one, insulin causes 
cortical actin remodeling, such that incoming vesicles can travel through the peripheral actin 
mesh to fuse with the plasma membrane (64) . The second suggests that actin filaments 
function as “highways,” upon which vesicles travel to reach the plasma membrane. 
Regardless of the exact actin function, it is apparent that insulin signaling to rearrange 
cortical actin represents a required pathway for optimal movement or fusion of GLUT4-
containing vesicles and plasma membranes. GLUT4 exocytosis and endocytosis are also 
regulated by microtubule network (65). Dynein and kinesins motor proteins are involved in 
these machanisms (66). 
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1.3.8 Role of SNARE proteins in  GLUT4 regulation 
 
After the insulin-mediated arrival of GLUT4-containing vesicles from intracellular storage 
sites to the plasma membrane, regulated fusion of these vesicles ensues. Exocytosis of 
GLUT4-containing vesicles is mediated by interactions between specific vesicular and 
plasma membrane protein complexes known as SNAREs. Vesicle SNAREs (v-SNARES, 
vesicle soluble N-ethylmaleimide-sensitive factor attachment protein receptors) bind target 
membrane SNAREs (t-SNAREs) in company with numerous accessory proteins. Syntaxin4 
and SNAP23 (23 kDa synaptosomal-associated protein) are the t-SNARES and VAMP2 is the 
v-SNARE involved in GLUT4 vesicle fusion (67)  While SNAREs are essential in GLUT4 
exocytosis, they themselves do not appear to be the direct targets of insulin action. Rather, 
studies suggest that the accessory proteins Munc18 and Synip may be regulated by insulin to 
accomplish fusion events. Three Munc18 isoforms (Munc18ac) have been identified in 
mammalian cells: Munc18a (67) is a neuronal isoform and Munc18b and Munc18c are 
expressed in muscle and adipose tissues. In addition to Munc18, the accessory protein Synip 
may also play a role in insulin stimulated GLUT4 vesicle fusion (68), although data are 
conflicting. Synip was first identified by Min and colleagues, who determined that this 
protein dissociates from syntaxin4 in an insulin-dependent manner and is directly involved 
in GLUT4 translocation. Recently, it was reported that Akt2 phosphorylates Synip on serine 
99 and this phosphorylation mediates the Synip-syntaxin4 dissociation necessary for GLUT4 
vesicle exocytosis (69). However, recent studies argue against this possibility and show that a 
serine-to-alanine Synip mutant (S99A) does not impair GLUT4 translocation.  
1.3.9 Role of GLUT4 dysfunctions  in obesity and type 2 diabetes 
 
 Insulin resistance is significantly caused by both genetic and environmental components. 
Mutations in the insulin receptor are rare but result in extremely severe insulin resistance. 
These include Leprechaunism, Rabson-Mendenhall Syndrome, and the type A syndrome of 
insulin resistance (70). Type 2 diabetes is polygenic, probably involving defects at numerous 
points in the glucose regulatory system. For example, skeletal muscle analyzed from type 2 
diabetic subjects displays diminished insulin-stimulated IRS-1 tyrosine phosphorylation and 
decreased PI3K activity coupled to impaired glucose transport. These defects could not be 
explained by alterations in protein expression. Likewise, skeletal muscle and adipocytes 
from obese, Type 2 diabetic patients demonstrate impaired insulin-triggered IRS-1 associated 
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PI3K activity (71), (44). Impaired insulin signaling through downstream Akt2 and AS160 
proteins has also been reported in skeletal  muscle. Furthermore, the fatty acid metabolite 
ceramide causes insulin resistance that is coupled to impaired membrane recruitment and 
phosphorylation of Akt (72). Knowledge on mechanisms of such defects has remained 
underdeveloped. Increased IRS-1 serine phosphorylation may also help explain insulin 
resistance, as phosphorylated serine residues are thought to sterically hinder interactions 
with downstream PI3K. Dysregulated PKC activity in insulin resistance could increase serine  
phosphorylation (73) and PKC knockout mice are protected from insulin resistance (74). 
 
Membrane and cytoskeletal defects are also a possible basis of insulin resistance. We now 
know that moderate increase in plasma membrane fluidity increase glucose transport . 
Furthermore, it has been shown that basal glucose transport is not fully active in fat cells and 
that it can be increased further by augmenting membrane fluidity. Consistent with 
membrane fluidity influencing insulin responsiveness, insulin-stimulated glucose transport 
is decreased when fluidity diminishes (75). Recent data suggest that the anti-diabetic drug 
metformin enhances insulin action by increasing membrane fluidity (76). Interestingly, the 
beneficial effects of chromium supplementation on insulin responsiveness may also be 
linked to membrane fluidity (77). With regards to cytoskeletal defects, recent study of 
various cell culture models of insulin resistance suggests that an underlying basis of reduced 
cellular insulin sensitivity may be perturbations in phosphoinositide-regulated cortical F-
actin structure. In particular, PI -P2 control of cortical F-actin is disturbed by 
hyperinsulinaemic (78) and hyperendothelinaemic insulin-resistant conditions (79). 
Furthermore, isolated adipocytes from ethanol-induced insulin resistant Wistar rats (80) and 
skeletal muscle from obese insulin-resistant Zucker rats display altered actin polymerization. 
These findings agree with the necessity of an intact cytoskeleton for proper glucose 
regulation and suggest a membrane/cytoskeletal component of insulin resistance. Finally, 
some study has also revealed that insulin-resistant conditions are associated with defects in 
the SNARE pathway. As future research continues to expand our understanding of the 
signaling pathways of insulinregulated GLUT4 translocation and glucose transport, our 
ability to develop interventions to prevent, reverse, and ameliorate insulin resistance in 
obesity and type 2 diabetes will be favourably reached. 
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1.4 The Serum and Glucocorticoid inducible Kinase SGK1 
 
The Serum and Glucocorticoid inducible protein Kinase 1 (SGK1) was originally cloned in  
1993 as an immediate early gene transcriptionally stimulated by serum or glucocorticoids 
in rat and mammary tumor cells  (81;82). Transcription of SGK1 was also shown to occur 
rapidly in response to many agonists like mineralocorticoids(83) , follicle stimulating 
hormone (FSH) (84), transforming growth factor (TGF- β) (85;86), thrombin (87), 
hypertonicity (88-90), high glucose (85;88) and neuronal injury or excitotoxicity (88;91;92) 
SGK1 belongs to the ‘AGC’ subfamily of serine/threonine protein kinases, which include 
protein kinase A (PKA) or adenosine 3’, 5’ monophophate (cAMP)-dependent protein 
kinase, protein kinase G (PKG) or guanosine 3’, 5’ monophosphate (cGMP)-dependent 
protein kinase and isoforms of protein kinase C (PKC). SGK1 is present in the genomes of 
all eukaryotic organisms examined so far, including Caenorhabditis elegans, Drosphila, fish 
and mammals. Structure of SGK1 has been highly conserved through evolution like many 
other protein kinases (90;93;94). 
 
Two other isoforms of SGK1 that have been identified in mammals and are named as SGK2 
and SGK3. The catalytic domains of SGK2 and SGK3 isoforms share 80% amino acid 
sequence identity with one another and with SGK1 (89). The human gene encoding SGK1 
was found in chromosome 6q23 (94) whereas the gene encoding SGK2 was identified in 
chromosome 20q12.  SGK-like gene which encodes a protein having predicted amino acid 
sequence identical to that of human SGK3 (95) was found in chromosome 8q12.2.  
 
SGK1 is expressed in humans that have been studied including the pancreas, liver, heart, 
lung, skeletal muscle, placenta, kidney and brain (90) but SGK1 is not expressed in all cell 
types within those tissues. For example, SGK1 transcript levels are found high in acinar 
cells in the pancreas (96). High transcript levels of SGK1 are also found in the distal tubule 
and collecting duct of the kidney and in thick ascending limb epithethial cells (85). The 
expression of SGK2 mRNA is restricted in human tissues. It expresses most abundantly in 
liver, kidney and pancreas (89). As like SGK1, SGK3 mRNA is present in all human and 
murine tissues examined but expression is particularly high in the mouse, heart and spleen 
and in the embryo (89;97). 
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SGK1 has been observed as cytosolic in differentiated cells such as luteal cells (84;93) or in 
tumour cells arrested in the G1 phase of the cell division cycle by glucocorticoids (84;98). It 
has also been observed as nuclear in proliferating glomerulosa cells (84;93;98) or mammary 
tumour cells during the S and G2-M phases of the cell cycle{Gonzalez-Robayna, 1999 514 
/id}. However, the localization of SGK1 in any given cell is regulated by extracellular 
signals. Thus, in serum-stimulated mammary epithelial cells, the endogenously expressed 
SGK1 is nuclear, but becomes cytosolic after the inhibition of phophatidylinositol (PI) 3-
kinase. Translocation from the cytosol to the nucleus also occurs in response to serum 
stimulation of HEK293 or COS cells transfected with SGK1(99).  
 
To become functional, SGK1 is activated by phosphorylation through a signaling cascade 
including phosphatidylinositol (PI) 3-kinase and phosphoinositide dependent kinase PDK1 
and PDK2/H-motif kinase. While PDK1 phosphorylates SGK1 at 256Thr, PDK2/H-motif 
kinase phosphorylates the kinase at 422Ser. SGK2 and SGK3 may similarly be activated by 
PDK1 and PDK2/H-motif kinase. The equivalent phosphorylation sites for SGK2 and 
SGK3 are found at 193Thr/356Ser and 253Thr/419Ser, respectively (89)  
 
Replacement of the serine at position 422 by aspartate in the human SGK1 leads to the 
constitutively active S422DSGK1 whereas replacement of lysine at position 127 with 
asparagine, within the ATP binding region required for the enzymatic activity, leads to the 
constitutively inactive K127NSGK1. Analogous mutations in SGK2 and SGK3 lead to the  
constitutively active S356DSGK2 and S419DSGK3, and the constitutively inactive K64NSGK2 and 
K191NSGK3 (89). 
 
SGK isoforms resemble PKB in the substrate specificity, recognizing a serine or threonine 
residue lying in Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr sequence (where Xaa is a variable amino 
acid) and thereby phosphorylating it (89). SGK1 has a considerable physiological role 
through the regulation of transporters and ion channels. Sodium channel conductance 
stimulated by SGK1 may result in cell volume regulation (88;90;100). SGK1 mediated 
activation of sodium channels leads to Na+ entry which in turn depolarizes the cell 
membrane. The depolarized cell membrane allows the entry of chloride ions and the 
accumulation of NaCl that further increases the intracellular osmolarity. The osmotic 
gradient makes water to enter the cell by which the volume of cell increases (94). SGK1 was 
found to stimulate Na+, K+ and 2Cl- cotransporter activity in the thick ascending limb of the 
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kidney, a key nephron segment in urinary concentration, which is of importance in renal 
Na+ reabsorption (85). Abundant SGK1 gene transcription has been observed in diabetic 
nephropathy (85-87), fibrosing pancreatitis (90) and inflammatory bowel disease (96) but 
SGK1 involvement in the formation of abnormal fibrosis tissues remains to be established.  
 
Moreover SGK1 and its isoforms are well proved in stimulating the activity and the cell 
membrane abundance of several transporters and ion channels. For instance, SGK isoforms 
regulate the epithelial Na+ channel, ENaC (101) , the voltage-gated Na+ channel, SCN5A 
(101;102), the K+ channels ROMK1 (103), KCNE1/KCNQ1 (104) and Kv1.3 (105), the 
Na+/H+ exchanger NHE3 (103), the dicarboxylate transporter NaDCT (103), the glutamate 
transporters EAAT1 (106), EAAT3 (107), EAAT4 (108) and EAAT5 (109) and the Na+/K+-
ATPase. The regulatory activity of SGK1 plays a diverse role in essential cell functions such 
as epithelial transport, excitability, cell proliferation and apoptosis.  
 
Individuals carrying a certain variant of SGK1 [the combined presence of distinct 
polymorphisms in intron 6(I6CC) and in exon 8 (E866) have been shown to associated with 
increased blood pressure.  It occurs due to enhanced stimulation of ENaC by SGK1.  
Moreover, the latter study revealed the role of SGK1 in the hypertension paralleling 
insulinemia.  The outlined SGK1 gene variant may further accelerate intestinal glucose 
absorption by stimulation of SGLT1 and glucose accumulation in peripheral tissues 
including fat.  Increased SGLT1 activity leads to accelerated intestinal glucose  absorption, 
excessive insulin release, fat deposition, a subsequent decrease of plasma glucose 
concentration, and triggering of repeated glucose uptake and thus obesity. 
 
 To date, two modes of SGK1 action in regulating transporters and ion 
channels have been identified. It either regulates transporters by phosphorylating them at 
the putative consensus site (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) or by inhibiting the 
downregulating effect of protein ubiquitin ligase Nedd4-2. These two modes of regulation 
of SGK1 were observed in epithelial Na+ channel, ENaC (110) (Figure 5). 
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Figure 5. Schematic model showing molecular mechanisms of ENaC regulation by SGK1. Aldosterone 
binding to the mineralocorticoid receptor (MR) can stimulates the transcription of SGK1 as well as ENaC. 
Insulin or Insulin-like growth factor (IGF-1) phosphorylates SGK1 at Ser422 through PI3 kinase and PDK2/H-
motify kinase signaling cascade. Activated (phosphorylated) SGK1 enhances ENaC plasma membrane 
abundance either directly by phosphorylating the channel or indirectly by inhibiting the downregulating effect of 
the ubiquitin ligase Nedd4-2.
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 2. AIM OF THE STUDY  
 
 Insulin stimulates glucose transport in hormone responsive tissues mainly by 
inducing the redistribution of the facilitated hexose carrier isoforms GLUT1 and GLUT4 
from intracellular compartments to the plasma membrane.  The cascade of signalling events 
involved in glucose transporter trafficking to the cell surface in response to insulin is 
triggered by an increase in insulin receptor tyrosine kinase activity followed by tyrosine 
phosphorylation of the insulin receptor substrates (IRS1, IRS2) and activation of the 
phosphatidylinositol 3-kinase (PI-3 kinase).  Downstream elements of PI-3 kinase include the 
phosphoinositide dependent kinase PDK-1 which in turn phosphorylates and thus activates 
the serine/threonine kinase Akt/protein kinase B (PKB) (111) (81). 
 
The role of PI-3 kinase in insulin-dependent and insulin-independent stimulation of GLUT1 
and GLUT4 translocation has been confirmed by several studies using pharmacological 
(Wortmannin) inhibition and genetic (PI-3 kinase dominant-negative mutants) knockout of 
the kinase .  The effect of PI-3 kinase on GLUT4 trafficking is mediated by PKB.  PKB is, 
however, at least in some cells, not required for the PI-3  dependent trafficking of GLUT1. 
Also results from cell culture experiments support a role of PKB and the atypical PKC 
isoforms (aPKCs) in the insulin-stimulated GLUT4 translocation. Coexpression of 
constitutively active PKB or aPKCs promotes glucose transport and persistent GLUT4 
localization to the plasma membrane, whereas expression of dominant-interfering PKB 
mutants or activation-resistant aPKCs inhibit glucose transport. Even though these inactive 
mutants reduced glucose transport, the insulin-mediated effect on glucose transport was not 
abrogated completely. Additionally, the ablation of PKBα or aPKCζ resulted in mice with no 
obvious defects in glucose homeostasis, indicating that additional PI3K dependent protein 
kinases are involved in the regulation of GLUT4. 
 
The role of PI-3 kinase in insulin-dependent and insulin-independent stimulation of GLUT1 
and GLUT4 translocation has been confirmed by several studies using pharmacological 
(Wortmannin) inhibition and genetic (PI-3 kinase dominant-negative mutants) knockout of 
the kinase .  The effect of PI-3 kinase on GLUT4 trafficking is mediated by PKB.  PKB is, 
however, at least in some cells, not required for the PI-3 dependent trafficking of GLUT1. 
Thus, some other PI-3 kinase dependent protein kinases are presumably involved in the 
regulation of GLUT1. 
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A further downstream molecule in PI-3 kinase signalling cascade is the serum-and 
glucocorticoid-inducible kinase SGK1.  The serum and glucorticoid inducible kinase SGK1 
regulates several transporters by enhancing their plasma membrane abundance.  Since 
GLUT1 contains a putative consensus site for phosphorylation by SGK1 at 95Ser, and GLUT4 
at 274Ser, the present study aimed at investigating whether these transporters are regulated 
by the kinase and whether the modulation occurs through changes in the transporter plasma 
membrane expression.   
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3. MATERIALS AND METHODS 
3.1 Chemicals and reagents 
Agar Agar      Roth, Karlsruhe, Germany 
Agarose electrophoresis grade,  Life Technologies, Paisley, Scotland 
Bovine serum albumin    Sigma-Aldrich, Deisenhofen, Germany 
Bromphenol blue     Sigma-Aldrich Chemie, Germany 
Chemoluminescence ECL kit   Amersham, Freiburg, Germany 
Collagenase D     Roche, Mannheim, Germany 
cRNA synthesis and DNAse I  
mMessage-mMachine kit,    Ambion, Austin,USA 
Developer and replenisher Biomax MR,  Eastman Kodak Company,NY, USA 
Diethylpyrocarbonate (DEPC)   Sigma-Aldrich, Deisenhofen, Germany 
Dimethylsulfoxide  (DMSO)    Sigma-Aldrich, Deisenhofen, Germany 
DNA-Ladder, 1 kb and 100bp   Life Technologies, Germany 
DNAase (RNAase free)    Roche, Mannheim, Germany 
dNTPs      Life Technologies, Germany 
Ethidium bromide     Sigma-Aldrich Chemie, Germany 
Fixer and replenisher    Biomax MR, Eastman Kodak   
      Company, Rochester NY, USA 
QuickChangeTM Site-directed    
Mutagenesis kit    Stratagene, Heidelberg, Germany 
Restriction enzymes                                      Boehringer, Mannheim, Germany 
Scintillation fluid Ultima Gold,   Packard, Groningen, the Netherlands 
3.2 Constructs and site-directed mutagenesis 
The constitutively active human S422DSGK1, T308DS473DPKB  and inactive human K127NSGK1 were 
kindly provided by Sir Philip Cohen (University of Dundee, Dundee, Scotland). The 
mutatated glucose transporter 4 S274AGLUT4  was generated by site-directed mutagenesis 
(QuikChange site-directed mutagenesis kit; Stratagene, Heidelberg, Germany) according to 
the manufacturer’s instructions.  
5´ CGTGAGCGGCCACTGGCCCTGCTCCAGCTCCTG 3´  
5´ CAGGAGCTGGAGCAGGGCCAGTGGCCGCTCACG 3´.  
The mutant was sequenced to verify the presence of the desired mutation. 
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3.3 Xenopus laevis oocytes 
 
One of the first and still most widely used assay system for quantifying an authentic protein 
biosynthetic process is the fully grown oocyte of the South African clawed frog, Xenopus 
laevis. The value of Xenopus laevis first became apparent in 1971, when Gurdon and co-
workers discovered that the oocyte constitutes an efficient system for translating foreign 
messenger RNA. 
 
The Xenopus oocyte is a cell specialized for the production and storage of proteins for later 
use during embryogenesis and developmentally divided into 6 stages (112). In addition, the 
complex architecture of the frog oocyte includes the subcellular systems involved in the 
export and import of proteins.  Therefore, the mRNA-microinjected oocyte is an appropriate 
system  to study the synthesis of specific polypeptides, as well as the storage of particular 
proteins in various subcellular organelles and the export of others into the extracellular space. 
Moreover, the subcellular compartmentalization, as well as the structure and biochemical, 
physiological, and biological properties of the synthesized protein, may be examined from 
exogenous proteins in the injected oocyte. For experimental studies oocytes of stages V-VI are 
used with a diameter of some 1.3 mm allowing easy preparation. The developmental stages 
V-VI are characterized by the occurence of 2 poles i.e. the vegetable (light) and the animal 
(dark) poles. 
 
The main ion conductance in Xenopus oocytes is a Ca2+-dependent Cl- conductance 
governing the resting membrane potential close to the Cl- reversal potential of -40 mV. 
Despite their advantages, several precautions should be taken into consideration. First, the 
expression of endogenous carriers may interfere with the exogenously expressed proteins in 
various ways. For instance, it has been observed that injection of heterologous membrane 
proteins at high levels can induce endogenous channels (113). Second, due to the fact that 
Xenopus laevis is a poikilothermic animal, its oocytes are best kept at lower temperature and 
most experiments are carried out at room temperature.  Hence, temperature sensitive 
processes i.e. protein trafficking or kinetics may be altered.  Finally, since Xenopus oocytes 
may have different signaling pathways, precaution should be taken when studying the 
regulation of expressed proteins.  It has been revealed that the PTH receptor regulates the 
internalization of the sodium-phosphate transporter NaPi, mediated by the PKA and PKC 
pathway. However, in NaPi-3 expressing Xenopus oocytes PKC-mediated PTH regulation 
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can not be observed. Instead, coupling to the PKA pathway leads to the alteration of PKA-
regulated ion channels (114). Exposing the Xenopus oocytes to the regulators of intracellular  
signaling such as PKC activator phorbol esters may unspecifically lead to internalization of 
the plasma membrane and the expressed proteins (115;116).  In summary, the Xenopus oocyte 
system has the advantage that channels, receptors and transporters can rapidly be expressed 
and identified by their electrophysiological properties. Once cDNA clones have been 
isolated, oocytes are an excellent system for correlating structure with function using a 
combination of molecular biological and electrophysiological techniques and analyzed both 
biochemically and electro physiologically in an in vivo situation.   
In this study we used Xenopus oocytes to express the facilitative glucose transporter GLUT1 
and to determine its putative modulation by the insulin-sensitive protein kinase SGK1.  
Advantages of the oocytes over other expression systems are that GLUT1 activity can be 
tested individually and that endogenous glucose transport is nearly detectable.  
Furthermore, the differential targeting of mammalian GLUT1 and GLUT4 is maintained in 
the Xenopus oocytes which suggests that the cellular apparatus controlling the intracellular 
targeting of GLUTs is conserved and that oocytes are a good expression system to elucidate 
the mechanism of GLUT regulation. 
3.3.1 In vitro RNA transcription 
 
In-vitro cRNA transcription involves 2 consecutive steps i.e. linearization of the plasmid 
DNA containing the inserted cDNA of interest by the corresponding restriction enzyme and 
the synthesis of RNA.   
a. The inserted DNA should be cut at the 3’ end yielding a 5’ protruding or a blunt end by 
restriction enzyme. Plasmid DNA (10 µg) was incubated with 20 U restriction enzyme and an 
10x buffer (5 µl) in a final volume of 50 µl at 37°C for 2 h or overnight. 
b. To ascertain the linearization process, a 5 µl aliquot was taken out and analysed on a 1% 
agarose. 
c. 1 volume isopropanol (50 µl) and 1/10 volume 3 M sodium acetate (5 µl) pH 5.2 was then 
added and incubated at room temperature for 10 min to precipitate the DNA. 
d. The precipitated DNA was recovered by centrifugation at 17,000 rpm for 15 min at 4°C. 
The DNA pellet was washed by adding 100 µl of cold 70% ethanol to the pellet followed by 
centrifugation at 17,000 rpm for 5 min at 4°C. This washing stage was repeated. The DNA 
pellet was air dried and then resuspended in 10 µl of DNase free H2O. The concentration of 
DNA was determined spectrophotometrically by measuring the absorbance at 260 nm. 
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e. 1 µg of linearised DNA was added to 1 µl rNTPS (20 nM), 2.5 µl Cap analogue (to prevent 
the degradation of the 5’ end of the synthesized RNA), 1 µl RNAase inhibitor (to protect the 
RNA from degradation by RNAase) and 2.4 µl 10 x transcription buffer(s). After mixing, 1 µl 
of T7 polymerase was added and the n incubated at 37°C for 1 hr. 1 µl DNase was added  
and the mixture was subsequently shaken for 15 min at 37°C. After addition of 100 µl DEPC-
water and 125 µl phenol chloroform, the mixture was centrifuged at 13,000 rpm for 2 min. 
f. To purify the generated RNA, 100 µl DEPC water and 125 µl of phenol-chloroform mixture 
was added and centrifuged at maximum speed for 2 minutes. The upper inorganic phase 
was carefully taken into a new eppendorf tube and 12.5 µl of 3 M sodium acetate (pH 5.2) 
and 375 µl of 100% ethanol was added and mixed by pulse vortex and further incubated at -
70ºCovernight.  
g.  After incubation, the mixture was centrifuged at 17000 rpm for 15 minutes at 4 ºC. The 
supernatant was removed and the pellet was washed twice with 200 µl of 70% ethanol. 
Finally the pellet was dried at room temperature and reconstituted in 25 µl of DEPC water 
and vortexed. Then concentration of RNA was measured by taking 1 µl of RNA in 69 µl 
water using an Eppendorf Biophotometer (Hamburg, Germany). The quality of the RNA 
generated was checked by gel electrophoresis. 
3.3.2 Preparation of Xenopus oocytes 
 
An adult female Xenopus laevis frog was submersed in one liter of 3- aminobenzoic acid ethyl 
ester (0.1%) for about 15-30 min (Figure 6A). After the frog was fully anesthetized it was 
placed on ice for surgery.   
 
A small abdominal incision (1 cm) was carried out and a segment of ovary was removed 
(Figure 6B,C). Subsequently the wound was closed with a reabsorbable suture (Figure 6D). 
The frog was then kept wet and warm by placing it in a cavity filled by a small amount of 
warm water to avoid drowning and hypothermia. 
 
The ovarial sacs were manually separated into groups of 10-20 oocytes, put into a 15 ml tube 
and then enzymatically defolliculated by treatment with an OR- 2 (Oocytes-Ringer) (Table 1) 
solution containing 1-2 mg/ml collagenase A for 2-2.5 h at room temperature (Figure 6E) 
with gentle agitation. Defolliculation of the oocytes was stopped by washing several times 
with ND96 (Table 1).This step also removes all detritus permitting oocyte sorting. Oocytes 
were then sorted using a self-made apparatus (Figure 6F). Only large oocytes (stage V or VI) 
were selected and stored overnight in a ND96 storage solution at 16°C.  
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Figure 6. Oocytes preparation and injection. A The frog is anesthetized in 1 liter of 3-aminobenzoic 
acid ethyl ester (1%) in tap water at near room temperature. B The frog is placed on its back during 
operation. An incision about 1 cm long is made in the skin. C A small portion of the ovary is pulled out 
with forceps and removed with a pair of scissors. D The peritoneum and the muscle tissue are sewn 
up and then the skin closed off using cat gut. E The clump of oocytes is immediately transferred to a 
petri dish containing modified Barth medium with antibiotic. F Oocytes of stage V and VI are separated 
with a platinum wire loop. G For injection, the oocytes are aligned relative to the tip of the needle. 
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ND96 
 
ND96 Storage 
solution 
 
OR-2 (Oocytes 
Ringer) 
 
NaCl (mmol/l) 96 96 82.5 
 
KCl (mmol/l) 2 2 2 
 
CaCl2 (mmol/l) 
1.8 1.8 - 
 
MgCl2 (mmol/l) 
1 1 1 
 
Tris-HEPES (mmol/l) 5 5 5 
 
Na-Pyruvate (mmol/l) - 2.5 2.5 
 
Theophylline(mmol/l) - 0.5 0.5 
 
Gentamycin (mmol/l) - 50 - 
pH 7.4 7.4 7.4 
 
Table 1. Composition of buffers used in Xenopus oocytes experiments 
3.3.3 cRNA injection 
 
After storing overnight, oocytes were injected using glass microcapillaries (filled with the 
required cRNA) mounted in a micromanipulator-controlled microinjector (Figure 7). 
Precaution was taken so that cRNA was not degraded by RNAases and that the injection 
capillary was not clogged with small particles.  To avoid those problems several procedures 
were carried out such as using only sterile pipettes, gloves and DEPC treated water for 
dilution of cRNA.  Glass capillaries were pulled using a normal puller. The tip was manually 
broken under the microscope (diameter of about 10-20 µm), backfilled with paraffin oil to 
seal the pipette from air and loaded with cRNA by suction (usually 1-2 µl).  Oocytes were 
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then placed into a 35 mm petri dish with a polypropylene mesh glued to the bottom to fix the  
oocytes and injected with a given volume of cRNA (usually 27.6 nl). The oocytes injected are 
listed in the Table 2. 
 
After injection, oocytes were kept in storage solution at 15°C. To avoid sticking of oocytes to 
the petri dish or to other oocytes, the dish was gently shaken. At least every two days the 
storage solution was exchanged and damaged oocytes were removed to maximise the 
survival of the oocytes. 
 
 
 
 
 
 
 
 
Figure 7. cRNA injection into the oocytes. In vitro transcribed poly (A)-cRNA is microinjected into 
the cytoplasm of the oocyte and in the following days the function of the encoded protein can be 
measured. 
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Table 2. Enzymes used for invitro transcription and amount of cRNA injected per oocyte. 
 
Isolation of mouse adipocytes 
 
Adipocytes were isolated from epididymal fat pads of 129/SvJ mice by collagenase digestion 
as described previously (117). Epididymal fat pads were minced and digested with 2 mg/ml 
type II collagenase for 1h at 37°C in Krebs Ringer bicarbonate Hepes buffer (KRBH: 120 
mmol/l NaCl, 4 mmol/l KH2PO4, 1 mmol/l MgSO4, 1 mmol/l CaCl2, 10 mmol/l NaHCO3, 
200 nmol/l adenosine, 30 mmol/l Hepes, pH 7.4) containing 1 % fraction V BSA. The 
resulting cell suspension was filtered through a nylon mesh (250 µm) and washed 3 times 
with KRBH buffer containing 3 % BSA. Then adipocytes were resuspended in KRBH buffer 
with 3 % BSA. An aliquot of the final cellular suspension was taken to measure lipocrit and 
cell number. 
3.5 Detection of cell surface expression by chemiluminescence 
 
To quantify the abundance of the transporters expressed on the plasma membrane of oocytes, 
chemiluminescence assay was employed. The protein expressed in the cell membrane is 
recognized first by the primary antibody which binds to an extracellular loop of the membrane 
protein.  Then the bound primary antibody forms a complex with the secondary antibody that 
is coupled with horse radish peroxidase, an enzyme that catalyzes a reaction giving a product 
and light.  The light is then detected by the luminometer. 
 
Defolliculated oocytes were first injected with constitutively active SGK1 (15 ng/oocyte) and 
1 day later with GLUT4 (10ng/oocyte). Initially the oocytes were incubated in a blocking 
solution of ND96 with 1% BSA solution for 30 minutes kept in ice. The oocytes were 
incubated with  2 µg/ml primary goat polyclonal anti-GLUT4 antibody which recognizes an 
N-terminal extracellular domain of GLUT4 (Santa Cruz Biotechnology, Heidelberg, 
Germany). This primary antibody treatment is done for 60 minutes kept in ice. After one 
Protein RNA polymerase cRNA injected (ng/nl) 
GLUT4 SP6 15 
GLUT4(SA) SP6 15 
S422DSGK1 T7 7.5 
K127NSGK1 T7 7.5 
PKB T7 7.5 
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hour of incubation, oocytes were washed with ND96/1%BSA solution for five times in 30 
minutes. Futher incubation is done in a solution 4 µg/ml secondary, peroxidase-conjugated 
donkey anti-goat IgG antibody (Santa Cruz Biotechnology, Heidelberg, Germany) for one 
hour. Oocytes were again washed in ND96/1%BSA solution for 10 times in one hour.  
Finally  oocytes were washed with ND96 buffer without BSA for 3 times in 15 mintues.  
Individual oocytes were placed in 96 well plates with 100µl of ND96 and 20 µl of SuperSignal 
ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL), and chemiluminescence 
was quantified by luminometry by integrating the signal over a period of 1 s.   
3.6 Tracer flux Measurements 
 
 Tritium-labeled 2-deoxy-D-glucose (2-DOG) was used as the glucose analogue for uptake 
determination. Groups of 10-15 oocytes injected with GLUT4 were incubated for 2 h with 1 
µM insulin. Thereafter oocytes were placed in 0.25 ml of ND96 (96 mmol/l NaCl, 2 mmol/l 
KCl, 1.8 mmol/l CaCl2, 1 mmol/l MgCl2 and 5 mmol/l HEPES, pH 7.4) containing 37 KBq 3H 
2-DOG and 50 µmol/l (or the indicated amount for kinetic analysis) of unlabeled 2-DOG. 
After incubation for 10 min at room temperature with 2-DOG (linear range of uptake), 
uptake was terminated by washing the oocytes four times with 3 ml of ice-cold phosphate-
buffered saline (PBS) containing 100 mmol/l 2-DOG. Oocytes were individually transferred 
into scintillation vials and dissolved by adding 200 µl of 10% SDS before radioactivity was 
determined. 
 
 In HEK-293 cells, 2-DOG uptake was measured 2 days after transfection by incubating cells 
at 37°C for 5 min (linear range of uptake) in glucose free krebs Ringer HEPES buffer 
containing 3H 2-DOG 0.1 µCi/well and 0.3 mmol/l cold 2-DOG with or without 0.1 mmol/l  
phloretein. Uptake was terminated by rapid aspiration of uptake solution and washing four 
times with ice-cold PBS containing 50 mmol/l unlabeled 2-DOG. Thereafter, cells were lyses 
with 10mmol/l NaOH/0.1%/Triton-X-100, and radioactivity incorporated into the cells was 
measured with a liquid scintillation counter. Protein concentrations were determined by the 
Bradford method. For kinetic analyis, 2-DOG uptake was  measured by incubating cells with  
3H 2-DOG 0.1 µCi/well and various concentrations of unlabeled 2-DOG at 37°C for 5 
minutes. 
 
In isolated adipocytes, 2-DOG uptake was measured by incubating the cells with 0.1 µCi 3H 
2-DOG and 0.1 mmol/l cold 2-DOG with or without 0.1 mmol/l phloretin. Uptake was 
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terminated after 5 min by centrifugation of cells through dinonylphthalate. The separated 
cells were removed from the top of the oil layer, and cell-associated radioactivity was 
quantified. 
 
3.7 Western blotting 
 
To determine whole-cell GLUT1 and SGK1 expression in HEK-293 and adipocytes,  cells were 
homogenized in lysis buffer and 30 µg protein were separated on a 10% polyacrylamide gel and 
transferred to a nitrocellulose membrane. After blocking with 5% non fat dry milk in PBS/0.15% 
Tween-20  for 1 h at room temperature, blots were incubated overnight at 4°C with a goat anti-
GLUT1 antibody (diluted 1:100 in PBS/0.15% Tween 20/5% nonfat dry milk; Santa Cruz 
Biotechnology),  a rabbit anti-SGK1 antibody (diluted 1:1,000 in PBS/0.15% Tween 20/5% 
nonfat dry milk; Upstate, Dundee, U.K.), or a rabbit anti–glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) horseradish peroxidase conjugated antibody (diluted 1:1,000 in 
PBS/0.15% Tween 20/5% nonfat dry milk). GAPDH was used to demonstrate equal protein 
loading. Secondary peroxidase-conjugated donkey anti-goat IgG antibody (diluted 1:2000 in 
PBS/0.15% Tween 20/5% nonfat dry milk; Santa Cruz Biotechnology) or sheep anti-rabbit IgG 
antibody (diluted 1:1,000 in PBS/0.15% Tween 20/5% nonfat dry milk; Amersham, Freiburg, 
Germany) was used for chemiluminescent detection of GLUT1 or SGK1 with an enhanced 
chemiluminescence kit (Amersham), respectively. Band intensities were quantified using 
Quantity One Analysis software (Biorad, Munich, Germany).  
 
To determine whole cell GLUT4 and SGK1 expression in oocytes and adipocytes, cells were 
homogenized in lysis buffer and 30 µg protein was separated on a 10 % polyacrylamide gel 
and transferred to a nitrocellulose membrane. After blocking with 5 % non-fat dry milk in 
PBS / 0.15 % Tween 20 for 1h at room temperature, blots were incubated overnight at 4 °C 
with a goat anti-GLUT4 antibody (Santa Cruz Biotechnology, Heidelberg, Germany, diluted 
1:100 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk), a rabbit anti-SGK1 antibody 
(Upstate, Dundee, UK) diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk or a 
rabbit anti-GAPDH HRP conjugated antibody (diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 
% non-fat dry milk). GAPDH was used to demonstrate equal protein loading. Secondary 
peroxidase-conjugated donkey anti-goat IgG antibody (Santa Cruz Biotechnology, 
Heidelberg, Germany), diluted 1:2000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk or 
sheep anti-rabbit IgG antibody (Amersham, Freiburg, Germany), diluted 1:1000 in PBS / 0.15 
% Tween 20 / 5 % non-fat dry milk was used for chemiluminescent detection of GLUT4 or 
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SGK1 with enhanced chemiluminescent ECL kit (Amersham, Freiburg, Germany) 
respectively. Band intensities were quantified using Quantity One® analysis software 
(Biorad, Munich, Germany). 
Calculations 
Data are provided as means ± SEM, n represents the number of oocytes investigated.  
All experiments were repeated with atleast three batches of oocytes. Uptake values were 
normalized in each batch of oocytes to the mean value obtained in oocytes expressing 
GLUT4 alone. GLUT4/GAPDH band intensities from three independent experiments were 
normalized to the mean value of GLUT4/GAPDH band intensity in oocytes expressing 
GLUT4 alone. For western blotting analysis of isolated adipocytes, GLUT4 band intensities 
were normalized to the value of GLUT4 intensity in adipocytes isolated from sgk1+/+ mice. 
Cell surface expression was normalized in each batch of oocytes to the mean relative light 
units value obtained in oocytes expressing GLUT4 alone. 
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4. RESULTS 
4.1 S422DSGK1 enhances GLUT4 mediated glucose transport in Xenopus 
oocytes 
To investigate the role of SGK1 in the modulation of insulin mediated GLUT4 activity, 
GLUT4 was expressed in Xenopus laevis oocytes and labelled 2 deoxy-glucose was measured 
in the presence of SGK1 and PKB protein kinase as the positive control. 
 
 
 
 
 
 
 
 
 
 
Figure 8. S422DSGK1 enhances GLUT4 mediated glucose transport.  Xenopus oocytes were 
injected with GLUT4 alone or along with constitutively active S422DSGK1 or constitutively active 
T308DS473DPKB. H2O injected oocytes served as control. 4 days after cRNA injection, labeled 2-DOG 
uptake was studied as a measure of GLUT4 activity. Arithmetic means ± SEM. * indicates statistically 
significant difference to uptake in Xenopus oocytes expressing GLUT4 alone. Uptake values were 
normalized in each batch of oocytes to the mean value obtained in oocytes expressing GLUT4 alone. 
 
Coexpression of the constitutively active S422DSGK1 in GLUT4-expressing oocytes resulted in 
an increase of radiolabeled 2-deoxy-glucose uptake (Figure 8, n = 24) while coinjection of 
S422DSGK1 in water-injected oocytes did not have any significant effect on intrinsic glucose 
transport (0.13 ± 0.01 pmol/min/oocyte, n = 26, in oocytes injected with S422DSGK1 alone vs. 
0.14 ± 0.01 pmol/min/oocyte, n = 26 in water-injected oocytes) demonstrating that the kinase 
does not affect intrinsic transporters. Coexpression of the constitutively active T308DS473DPKB,  
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used as a positive control, strongly activated glucose uptake as expected (Figure 8, n = 22). 
Expression of T308DS473DPKB alone did not significantly increase glucose uptake (0.15 ± 0.01 
pmol/min/oocyte, n = 24, in oocytes injected only with T308DS473DPKB vs. 0.14 ± 0.01 
pmol/min/oocyte, n = 26 in water-injected oocytes). 
4.2 SGK1 catalytical activity is involved in the upregulation of GLUT4 
activity 
 
GLUT4 stimulation by S422DSGK1 was dependent on the catalytic activity of the kinase as the 
inactive mutant K127NSGK1 did not enhance but slightly inhibited the transporter (55.9 ± 3.3 % 
of control, n = 18, Figure 9). This result indicates that phosphorylation processes are involved 
that culminate in stimulation of GLUT4 expression. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. S422DSGK1 catalytical activity is required for the upregulation of GLUT4. 
 Xenopus oocytes were injected with GLUT4 alone or along with constitutively active S422DSGK1 or 
inactive K127NSGK1. H2O injected oocytes served as control. 4 days after cRNA injection, labeled 2-
DOG uptake was studied as a measure of GLUT4 activity. Arithmetic means ± SEM. * indicates 
statistically significant difference to uptake in Xenopus oocytes expressing GLUT4 alone. Uptake 
values were normalized in each batch of oocytes to the mean value obtained in oocytes expressing 
GLUT4 alone. 
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4.3 GLUT4 maximal transport rate is enhanced by S422DSGK1  
 
To determine whether the kinase modulates GLUT4 kinetic properties, GLUT4 activity was 
measured at different 2-DOG concentrations in the absence and presence of  S422DSGK1. Data 
obtained revealed that SGK1 enhances GLUT4 by modifying the maximal transport rate, 
Vmax, without affecting substrate affinity (Figure 10) (Table 3).  
 
 
 
 
 
 
 
 
 
 
Figure 10.   GLUT4 maximal transport rate is increased by S422DSGK1. Xenopus oocytes were 
injected with water or with GLUT4 alone or along with constitutively active S422DSGK1. 4 days after 
cRNA injection, 2-DOG uptake was measured at the indicated substrate concentrations. Uptake 
values of water-injected Xenopus oocytes were subtracted and results were normalized in each batch 
of oocytes to the Vmax obtained in oocytes expressing GLUT4 alone. Arithmetic means ± SEM. 
 
 
 
 
 
 
Table 3. Kinetic parameters of GLUT4 coexpression of S422DSGK1 in Xenopus oocytes.  
 
Injected cRNA 
 
Km (mmol/l) 
 
Vmax (normalised) 
 
GLUT4 
 
8.08 ± 0.95 
 
 
1.20 ± 0.52 
 
 
GLUT4+SGK1(SD) 
 
10.85 ± 1.02 
 
 
6.78 ± 2.32 
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4.4  S422DSGK1 stimulates GLUT4  plasma membrane abundance without 
affecting total GLUT4 proten levels 
 
SGK1 might increase GLUT4 activity by promoting GLUT4 synthesis or by increasing 
GLUT4 abundance at the plasma membrane.  
 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. S422DSGK1 stimulates GLUT4 activity by promoting GLUT4 plasma membrane 
abundance without affecting total GLUT4 protein levels. 
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According to western blotting of whole oocyte lysates, enhanced GLUT4 activity is not the 
result of increased GLUT4 protein synthesis (Figure 11A). GLUT4 protein levels remained 
similarly unaffected in adipocytes isolated from sgk1-/- mice (Figure11B). 
 
Total GLUT4 expression was assessed by western blotting of whole cell lysates from oocytes 
expressing GLUT4 alone or along with S422DSGK1 (A), and in adipocytes isolated from sgk1+/+ 
and sgk1-/- mice (B). Arithmetic means ± SEM. GLUT4/GAPDH band intensities from three 
independent experiments were normalized in each batch to the mean value of 
GLUT4/GAPDH band intensity of cells expressing GLUT4 alone. For western blotting 
analysis of isolated adipocytes, GLUT4 band intensities from three independent experiments 
were normalized to the value of GLUT4 intensity in adipocytes isolated from sgk1+/+ mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. S422DSGK1 upregulates GLUT4 plasma membrane abundance in cell surface 
expression experiment. Xenopus oocytes were injected with GLUT4 alone or along with 
constitutively active S422DSGK1 or inactive K127NSGK1. H2O injected oocytes served as control. 4 days 
after cRNA injection, labeled 2-DOG uptake was studied as a measure of GLUT4 activity. Arithmetic 
means ± SEM. * indicates statistically significant difference to uptake in Xenopus oocytes expressing 
GLUT4 alone. Uptake values were normalized in each batch of oocytes to the mean value obtained in 
oocytes expressing GLUT4 alone. 
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To test whether SGK1 enhances GLUT4 activity by altering its trafficking to the plasma 
membrane, GLUT4 cell surface abundance in Xenopus oocytes was examined upon 
coexpression of S422DSGK1 by quantitative immunoassays. Oocytes coexpressing T308DS473DPKB 
were used as a positive control. Figure 12 shows that the relative surface abundance of the 
transporter is more prominent in oocytes expressing S422DSGK1 or T308DS473DPKB along with 
GLUT4 than in oocytes expressing GLUT4 alone (n = 36). 
 
4.5 GLUT4 transporter stimulation by S422DSGK1 is abrogated upon 
disruption of putative SGK phosphorylation site on GLUT4 
 
GLUT4 bears a putative SGK1 phosphorylation site on its sequence at 274Ser. To determine 
whether SGK1 modulates GLUT4 uptake by phosphorylating GLUT4, the serine at position 
274 in GLUT4 was mutated into alanine (S274AGLUT4) and its regulation evaluated upon 
coexpression of the kinase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. S422DSGK1 upregulates GLUT4 activity  by the direct phosphorylation machanism. 
Xenopus oocytes were injected with wild-type GLUT4 or S274AGLUT4 alone or along with constitutively 
active S422DSGK1. 4 days after cRNA injection, labeled 2-DOG uptake was studied (A) and western 
blotting performed to demonstrate proper S422DSGK1 expression. Arithmetic means ± SEM. * indicates 
statistically significant difference to uptake in Xenopus oocytes expressing wild-type GLUT4 or 
S274AGLUT4 alone. Uptake values were normalized to the mean value obtained in oocytes expressing 
wild-type GLUT4 alone. 
2-
D
eo
xy
-
G
lu
co
se
 
Up
ta
ke
(no
rm
a
liz
ed
)
0
1
2
3
4
*
H2
O
GL
UT
4
GL
UT
4 +
 
S4
22
D SG
K1
S2
74
A GL
UT
4 
S2
74
A GL
UT
4 +
 
S4
22
D SG
K1
 40 
Ablation of the putative SGK phosphorylation site blunted significantly GLUT4 stimulation 
despite proper S422DSGK1 expression (120 ± 21 % of 2-DOG uptake measured in S274AGLUT4 
expressing oocytes, n = 39, Figure 13). 
 
 
 
 
 
 
 
 
Figure 14. Direct phosphorylation machanism is not involved in the regulation of GLUT4 by 
PKB. Xenopus oocytes were injected with wild-type GLUT4 or S274AGLUT4 alone or along with 
constitutively active T308DS473DPKB. 4 days after cRNA injection, labeled 2-DOG uptake was studied in 
wild-type GLUT4 and in S274AGLUT4 expressing oocytes. Arithmetic means ± SEM. * indicates 
statistically significant difference to uptake in Xenopus oocytes expressing wild-type GLUT4 or 
S274AGLUT4 alone. 
 
The effect of T308DS473DPKB on the GLUT4 phosphorylation-deficient mutant (S274AGLUT4) was 
similarly analyzed. As shown in Figure 14, mutation of the putative phosphorylation site on 
GLUT4 did not alter the ability of T308DS473DPKB to activate GLUT4 (199.9 ± 34.4 % of 2-DOG 
uptake measured in S274AGLUT4 expressing oocytes, n = 33). 
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4.6 S422DSGK1 enhances 2-DOG transport in HEK-293 cells without 
affecting total protein expression levels of GLUT1 
 
It was already observed the upregulation of GLUT1 by SGK1 in Xenopus oocytes. GLUT1 
modulation by SGK1 was  observed in mammalian cells (HEK-293). HEK-293 cells were 
transfected with pIRES2EGFP-S422DSGK1, pIRES2EGFPK127NSGK1 or with empty vector (as a 
control) and two days later 2-DOG uptake was measured in the presence and absence of 
GLUT1 inhibitor phloretin (0.1 mM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. S422DSGK1 enhances 2-DOG transport in HEK-293 cells without affecting total 
GLUT1 expression levels. HEK-293 cells were transfected with pIRES2EGFP-S422DSGK1, 
pIRES2EGFPK127NSGK1 or empty vector and 2 days later, labeled 2-DOG uptake was studied in the 
presence and absence of GLUT1 inhibitor 0.1 mM phloretin   
 
Tracer-flux studies revealed an increase in GLUT1 transport rate (from 2.3 ± 
0.6nmol/min/mg protein, n = 3, to 5.1 ± 0.6 nmol/min/mg protein, n = 3, Figure 15) upon 
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coexpression of S422DSGK1. As observed in Xenopus oocytes, GLUT1 upregulation by SGK1 
was dependent on the catalytic activity of the kinase as the effect was lacking upon 
expression of the catalytical inactive mutant K127NSGK1 (from 2.3 ± 0.6nmol/min/mg protein, 
n = 3, to 1.8 ± 0.2 nmol/min/mg protein, n = 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Western blots of whole cell lysates were performed . Arithmetic means ± SEM. * indicates 
statistically significant difference to uptake in HEK-293 cells transfected with the empty vector (*p < 
0.05).  
 
Western blotting of whole cell lysates indicated that the kinase fails to induce GLUT1 protein 
synthesis (Figure 16). For western blotting, GLUT1/GAPDH band intensities from three 
independent experiments were normalized in each transfection to the value of 
GLUT1/GAPDH band intensity of oocytes expressing GLUT1 alone. 
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4.7 Enhancement of GLUT1 maximal transport rate upon S422DSGK1 
transfection into HEK-293 cells 
 
 
 
Figure 17. S422DSGK1 elevates GLUT1 maximal transport rate. HEK-293 cells were transfected with  
pIRES2EGFP-S422DSGK1, pIRES2EGFPK127NSGK1 or empty vector. 2 days after transfection, labeled 
2-DOG uptake was studied at the indicated substrate concentrations. Arithmetic means ± SEM. 
 
 
Tranfected DNA 
 
 
Km (mmol/l) 
 
Vmax 
(nmol/min/mg
 
protein) 
 
pIRES2EGFP 
 
 
0.95±0.44 
 
17.74±2.31 
 
pIRES2EGFP- S422DSGK1 
 
2.89±0.85 44.93±4.40(P<0.05) 
 
pIRES2EGFP- K127NSGK1 
 
2.30±1.38 22.37±4.81 
 
Table 4. Kinetic parameters of GLUT1 upon transfection of pIRES2EGFP- S422DSGK1 
pIRES2EGFP- K127NSGK1, or empty vector into HEK -293 cells. 
 44 
 
Kinetic analysis of 2-DOG uptake in transfected HEK-293 cells revealed that S422DSGK1 
enhances GLUT1 by modifying the maximal transport rate, Vmax (from 17.7 ± 2.3 
nmol/min/mg protein, n = 3, to 44.9 ± 4.4 nmol/min/mg protein, n = 3) thereby 
corroborating the results obtained in the Xenopus oocyte expression system (Figure 17 and 
Table 4). 
 
4.8 GLUT1 mediated glucose transport is reduced in adipocytes isolated 
from SGK1 knockout mice 
 
Tracer flux studies in adipocytes isolated from sgk1+/+ and sgk1-/- mice demonstrated the 
role of SGK1 in glucose transport regulation. As depicted in Figure 18A, 2-DOG uptake was 
lower (55.67 ± 16.46 %) in adipocytes isolated from sgk1-/- mice compared to sgk1+/+ mice 
despite similar total GLUT1 expression levels (Figure 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18A. Glucose transport is reduced in adipocytes isolated from sgk1-/- mice 
Adipocytes were isolated from sgk1+/+ and sgk1-/- mice and 2-DOG uptake studied in the presence 
and absence of 0.1 mM phloretin (in A) or western blots of whole cell lysates were performed (in B). 
Arithmetic means ± SEM. * indicates statistically 25 significant difference to uptake in adipocytes 
isolated from sgk1+/+ mice (*p < 0.05). 
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Figure 18B. Glucose transport is reduced in adipocytes isolated from sgk1-/- mice 
Adipocytes were isolated from sgk1+/+ and sgk1-/- mice and 2-DOG uptake studied in the presence 
and absence of 0.1 mM phloretin (in A) or western blots of whole cell lysates were performed (in B). 
Arithmetic means ± SEM. * indicates statistically 25 significant difference to uptake in adipocytes 
isolated from sgk1+/+ mice (*p < 0.05). For western blotting, GLUT1 band intensities from three 
independent experiments were normalized to the value of GLUT1 intensity in adipocytes isolated from 
sgk1+/+ mice. 
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5. Discussion 
 
Insulin-induced translocation of GLUT4 and  GLUT1 to the plasma membrane requires the 
activity of phosphatidylinositol 3-kinase. The phosphoinositide signal is transmitted through 
PDK1 and its downstream targets PKB and atypical PKCs (118-122). The role of these kinases 
in regulating the gain in GLUT4 surface abundance has been supported by the use of 
dominant-negative mutants {Bandyopadhyay, 2000 171 /id;Cong, 1997 4502 /id}. Although 
PKB and atypical PKCs are involved in the insulin-stimulated GLUT4 translocation they do 
not fully account for the recruitment of GLUT4 to the plasma membrane (123). Thus, 
additional signalling pathways may participate through  PI3K activation. The role of PI-3 
kinase in insulin-dependent and insulin-independent stimulation of GLUT1 and GLUT4 
translocation has been confirmed by several studies using pharmacological (wortmannin) 
inhibitin and genetic knockout of the kinase. The effect of PI-3 kinase on GLUT4 trafficking is 
mediated through PKB. PKB is, however, atleast in some cells, not required for the PI-3 
dependent signaling of GLUT1. Thus some other PI-3 dependent protein kinases are 
presumably involved in the regulation of GLUT1 and insulin mediated GLUT4 signaling. 
 
SGK1 is a further downstream molecule in the PI3K signalling cascade that regulates cell 
surface expression of several metabolite transporters and ion channels.  
 
In the present study we demonstrate that SGK1 induces the activity of GLUT4 
heterologously expressed in Xenopus oocytes. Like its close relative PKB, SGK1 stimulates 
GLUT4-mediated transport by augmenting GLUT4 abundance in the plasma membrane. 
Adipocytes express GLUT1 and GLUT4 (124). Whereas GLUT4 is present in intracellular 
compartments in unstimulated adipocytes, GLUT1 is mainly located in the plasma 
membrane. The differential targeting of mammalian GLUT1 and GLUT4 is maintained when 
these proteins are expressed in Xenopus oocytes (125) which suggests that the cellular 
apparatus controlling the intracellular targeting of GLUT4 is conserved in Xenopus oocytes 
and that oocytes are a good expression system to elucidate the mechanism of GLUT4 
targeting. Other investigators have examined GLUT4-mediated transport in oocytes to 
evaluate the effect of insulin and IGF-I on glucose uptake and glucose transporter 
distribution (126;127). Additional advantages of oocytes are that specific GLUT transporters 
can be tested individually and that endogenous glucose transport is negligibly low. 
Furthermore exogenous SGK1 expression did not significantly increase intrinsic glucose 
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uptake in control oocytes demonstrating that it is not effective through activation of 
endogenous transporters. 
 
In theory, SGK1 might increase GLUT4 activity by promoting GLUT4 synthesis. However, 
the stimulation of glucose transport in Xenopus oocytes in which GLUT4 cRNA has been 
injected points to posttranscriptional regulation of GLUT4. Enhanced GLUT4 activity is also 
not due to the result of increased GLUT4 translation (Figure 2A, B). 
 
The kinase exerts its effects at least in part by phosphorylating GLUT4 directly as indicated 
by our coexpression studies. A direct GLUT4 phosphorylation by PKCζ has been 
demonstrated in GLUT4-containing vesicles purified from low density microsomes of rat 
adipocytes. GLUT4 phosphorylation was increased in insulin treated cells suggesting that 
transporter phosphorylation might be required in GLUT4 translocation mechanism in 
adipocytes. Although SGK1 and PKB recognize the same phosphorylation site on their target 
proteins, there is no evidence that PKB phosphorylates GLUT4 directly. This could be 
explained by the fact that residues neighbouring the putative phosphorylation site can 
influence the phosphorylation efficiency by the kinases (128). 274Ser in the GLUT4 sequence is 
followed by a leucine. Kobayashi et al. (128) demonstrated by in vitro kinase assays that 
SGK1 phosphorylates targets with a leucine residue next to the phosphorylation site more 
efficiently than PKB. Our observations on the ability of PKB to stimulate the 
phosphorylation-deficient GLUT4 mutant (S274AGLUT4) support the notion that PKB effects 
do not require the putative phosphorylation site on GLUT4. SGK1-dependent stimulation of 
GLUT4 transporters may be of relevance in the cellular uptake of glucose into muscle and 
adipose cells. In fact SGK1 dependent regulation of glucose transport is reflected by delayed 
glucose uptake into skeletal muscle and fat tissue in the sgk1 null mouse following an 
intraperitoneal glucose tolerance test. It has been already shown that SGK1 upregulates the 
facilitative glucose transporter GLUT1 in its constitutive form by using Xenopus oocytes model 
system. On the other hand, the kinase dead SGK1 does not upregulate the activity of GLUT1 
which suggests that the catalytical activity of the kinase is required for the upregulatory 
mechanism. 
Phosphorylation dependent events have previously been shown to modulate GLUT1 
activity. Protein kinase C isozymes stimulate the activity of GLUT1 by recruiting the transporter 
to the cell surface. The kinase stimulates GLUT1 by enhancing the transporter plasma 
membrane abundance through phosphorylation of an unknown intermediate protein. 
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According to our results, SGK1 could play a similar role in the regulation of GLUT1 as PKB 
plays in the regulation of GLUT4. In some studies on adipocytes, constitutively active PKB 
has been able to upregulate GLUT4 but not GLUT1 (129). Insulin, however, upregulated both 
GLUT1 and GLUT4, and both effects were abrogated by inhibition of PI3 kinase (129) . On 
the other hand, dominant inhibitory PKB has been shown to inhibit the insulin-mediated 
increase in GLUT1 protein abundance (130) , and PKB has been reported to stimulate GLUT1 
translocation to the cell membrane (131), suggesting a role of PKB in the regulation of 
GLUT1. Moreover, insulin may (129;129)  or may not (132) stimulate GLUT1. Thus, the 
regulation of GLUT1 may depend on the experimental condition and may be supported by 
PKB and/or SGK1. It should be kept in mind that the transcription of SGK1 is highly variable 
and subject to a number of regulators (81;132) , and thus SGK1-dependent effects may be 
similarly variable. GLUT1 modulation by SGK1 in cultured mammalian cells and  adipocytes 
isolated from sgk1–/– mice points to a physiological role of the kinase in glucose transport 
regulation.  
Facilitated GLUT1 transporter deficiency syndrome defines a prototype of a novel group of 
disorders resulting from impaired glucose transport across blood barriers.  It is caused by the 
defect of glucose transport into the brain, mediated by the glucose transporter GLUT1.The 
hallmark of this disease is a low glucose concentration in the CSF.  Clinical features are 
variable and include seizures, developmental delay, acquired microcephaly, hypotonia, 
dystonia and spasticity.  Increased expression of this gene has been shown  in the rat cortex 
at 24  hours after focal cerebral ischemia. Notably, SGK1 expression is upregulated by 
cerebral ischemia and may help to enhance cellular glucose uptake into the ischemic tissue. 
Moreover, the enhanced cerebral SGK1 expression in enriched environment my serve to 
adjust glucose uptake into several tissues in the SGK1 knockout mouse following an 
intraperitoneal glucose tolerance test.  
The SGK1-dependent regulation of GLUT1 may participate in the adjustment of cellular 
glucose uptake to the demand.  Similarly to GLUT4, SGK1 activates GLUT1 by promoting the 
transporter´s cell surface expression without impacting the total GLUT1 protein abundance. 
In contrast to GLUT4, the putative SGK1 phosphorylation site on GLUT1 is not essential for 
transport modulation by the kinase. 
SGK1-dependent stimulation of GLUT4 transporters may be of relevance in the cellular 
uptake of glucose into muscle and adipose cells. In fact SGK1 dependent regulation of 
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glucose transport is reflected by delayed glucose uptake into skeletal muscle and fat tissue in 
the sgk1 null mouse following an intraperitoneal glucose tolerance test . 
 
In conclusion, SGK1 stimulates glucose transport by enhancing the abundance of the facilitative 
glucose transporter GLUT4 in the cell membrane at least in part via direct GLUT4 
phosphorylation. Whereas in the case of GLUT1,  it enhances the transporter in the plasma 
membrane through phosphorylation of a hitherto unknown intermediate protein. The SGk1 
dependent regulation of GLUT1 may participate in the adjustment of cellular glucose uptake 
to the demand. The observations disclose a novel PI3K target participating in the regulation of 
glucose transport. 
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